ADMS Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the following investor conferences:

• SVB Leerink Global Healthcare Conference on Thursday, February 27 at 9:00-9:25 a.m. ET(6:00 a.m. PT)

• Cowen Annual Healthcare Conference on Wednesday, March 4 at 9:20 a.m.-9:50 a.m. ET (6:20 a.m. PT)

The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. An archived version of the webcast will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com.

Contact:Investors: Peter VozzoManaging Director, Westwicke443-213-0505peter.vozzo@westwicke.com

Media: Sarah MathiesonVice President of Corporate Communications510-450-3528smathieson@adamaspharma.com